Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. - Wikidata - awgldk - TriplyDB

Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.

Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.

http://www.wikidata.org/entity/Q37190771

about

Efflux-mediated drug resistance in bacteria: an update Two-component regulatory systems in Pseudomonas aeruginosa: an intricate network mediating fimbrial and efflux pump gene expression The regulatory repertoire of Pseudomonas aeruginosa AmpC ß-lactamase regulator AmpR includes virulence genes Polyamino-Isoprenic Derivatives Block Intrinsic Resistance of P. aeruginosa to Doxycycline and Chloramphenicol In Vitro Evolution of the Pseudomonas aeruginosa mutational resistome in an international Cystic Fibrosis clone The contribution of antibiotic resistance mechanisms in clinical Burkholderia cepacia complex isolates: an emphasis on efflux pump activity.Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis.Mini-review: Lactoferrin: a bioinspired, anti-biofilm therapeutic Clonal dissemination, emergence of mutator lineages and antibiotic resistance evolution in Pseudomonas aeruginosa cystic fibrosis chronic lung infection.AmgRS-mediated envelope stress-inducible expression of the mexXY multidrug efflux operon of Pseudomonas aeruginosa.Multidrug efflux pumps from Enterobacteriaceae, Vibrio cholerae and Staphylococcus aureus bacterial food pathogens Coexistence and within-host evolution of diversified lineages of hypermutable Pseudomonas aeruginosa in long-term cystic fibrosis infections.The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria.Role of the MexEF-OprN efflux system in low-level resistance of Pseudomonas aeruginosa to ciprofloxacin The cystic fibrosis microbiome in an ecological perspective and its impact in antibiotic therapy.Sequential Treatment of Biofilms with Aztreonam and Tobramycin Is a Novel Strategy for Combating Pseudomonas aeruginosa Chronic Respiratory Infections.Pseudomonas aeruginosa syntrophy in chronically colonized airways of cystic fibrosis patients.MexXY multidrug efflux system of Pseudomonas aeruginosa.Resistance-Nodulation-Division Multidrug Efflux Pumps in Gram-Negative Bacteria: Role in Virulence Mutational activation of the AmgRS two-component system in aminoglycoside-resistant Pseudomonas aeruginosa.Key two-component regulatory systems that control biofilm formation in Pseudomonas aeruginosa.Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria.Microbial siderophores: a mini review.Adaptive and mutational resistance: role of porins and efflux pumps in drug resistance.Biotechnological domestication of pseudomonads using synthetic biology.Evolution and impact of bacterial drug resistance in the context of cystic fibrosis disease and nosocomial settings.Multiple mutations and increased RNA expression in tetracycline-resistant Streptococcus pneumoniae as determined by genome-wide DNA and mRNA sequencing.Interplay Between Antibiotic Resistance and Virulence During Disease Promoted by Multidrug-Resistant Bacteria.Two-component systems required for virulence in Pseudomonas aeruginosa.Cooperative pathogenicity in cystic fibrosis: Stenotrophomonas maltophilia modulates Pseudomonas aeruginosa virulence in mixed biofilm.Oxidative stress induction of the MexXY multidrug efflux genes and promotion of aminoglycoside resistance development in Pseudomonas aeruginosa Polymyxin Susceptibility in Pseudomonas aeruginosa Linked to the MexXY-OprM Multidrug Efflux System.Mechanisms of intrinsic resistance and acquired susceptibility of Pseudomonas aeruginosa isolated from cystic fibrosis patients to temocillin, a revived antibiotic.Characterization of clonal strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients in Ontario, Canada.Antibiotic inducibility of the mexXY multidrug efflux operon of Pseudomonas aeruginosa: involvement of the MexZ anti-repressor ArmZ.Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance.Insights into the evolution of the mutational resistome of Pseudomonas aeruginosa in cystic fibrosis.MexXY efflux pump overexpression and aminoglycoside resistance in cystic fibrosis isolates of Pseudomonas aeruginosa from chronic infections.Evolution of the Pseudomonas aeruginosa aminoglycoside mutational resistome in vitro and in the cystic fibrosis setting.Aminoglycoside resistance of Pseudomonas aeruginosa in cystic fibrosis results from convergent evolution in the mexZ gene.

P2860

Q24609407-8F766171-CC1B-471D-AB7E-C1FBF44D5508 Q28492999-6F0858E9-5C35-4B4E-8128-51654B4808E0 Q28493156-11CCD836-1914-4D8B-9838-A4417B4CB836 Q28551861-6D525F31-E4A1-4740-8B31-7D45B7FD377B Q33911762-4D61707F-9813-451A-BA9F-336954E8A685 Q34083595-44487AB9-2ADC-4FCF-AB2C-2CF7DD211B74 Q34309282-536C6EF7-B052-4CF9-A9D3-27DD99E1C33A Q34650340-C8A5531D-E6F0-495A-BBD6-2192C10ED44D Q34948367-81CB3D55-4294-4374-8CD5-8DD72D80FEB8 Q35106217-7811051D-2A91-4B7B-B4AF-0D31B8B17E89 Q35131669-9B8A0583-311D-427A-B09D-A4B9BC0F2DD5 Q35350270-550F887F-F1B8-4B59-AF5A-D95D6A4FD35D Q35482558-D0648D9D-F3F5-4577-BE2F-525707FF13D1 Q35598576-54297066-E246-4BD5-ACB3-5BB31250CA40 Q35861377-B17A703D-9C49-4632-987B-4D8C2B7550D4 Q35939649-F2BE3A4A-33BF-41AD-95F4-ED126AA3C3B8 Q36364034-B7C5AECA-6E12-421C-80D7-6055A407D960 Q36450695-8216F551-89A3-4A33-A7F0-1C067FF736A7 Q36683498-1349A08E-4A49-4619-98B7-3BFA8929C704 Q36785893-4EAEA55E-8A62-4225-A39C-8BC6954BDACD Q37873565-531D7162-D9FB-43F5-990A-D2837613D949 Q37894832-73A7CAFB-D110-47B3-8318-96AD9815A298 Q38021726-F1501A5B-0C29-4A15-9AAD-F568713C8798 Q38049220-C01200D5-BCEB-41E2-875C-FDCD61DD7836 Q38204897-E7AAC189-A051-429C-9408-DF15376C0623 Q38211644-4AFF4E43-CE6D-48BD-9F97-3CF7E62C5DB0 Q38464738-5998340F-4FD0-40C9-8739-F3EC75A10E00 Q39218893-54309DF6-E0A0-4ED8-B6C0-B4624FE1966B Q40210470-E1ACF9D4-630A-48EF-8B7F-1CEC241417E8 Q40964077-10C2483B-87A8-4E12-8785-2A2339D4BC2E Q41841534-76B3A18B-27FE-4485-8ABB-052AF7A46297 Q42027703-EFE2AD48-E643-4921-ABCE-77B3383FBC3C Q42330262-486BAB23-043C-4F0C-9BBB-C8D4EB22C8D6 Q42961660-687A86A3-63E7-4A90-AE27-8F8CC136C4BC Q43245264-FC832594-7401-47D3-B360-7DCE6C4D1BE7 Q47748447-51CAAEA9-0676-4DE3-B5B5-D7F604744F5B Q47877807-CCDAE5A0-C8F6-4ED5-9FB2-9049CBE74498 Q50042713-F6F2AE18-843F-45D6-914C-CA0FA1033D5E Q50044370-630DA4F0-DC04-4A5D-A8EA-C326446EEEEA Q50282134-767A7997-210A-4873-982C-D9E2B21AD263

P2860

Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.

http://www.wikidata.org/entity/Q37190771

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 02 March 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.

@en

Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.

@nl

type

label

Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.

@en

Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.

@nl

prefLabel

Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.

@en

Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.

@nl

P1433

Q37190771-EF7B664F-3CFE-4B56-B706-59C1577E01A4

P1476

Q37190771-FBC50B05-B2D8-4A98-BD05-004EBCDC657E

P2093

Q37190771-0A5E34B5-DAEF-4796-86D8-E9A0D7F75EB4

Q37190771-3731737D-7D4D-4CF0-9157-CC2D0CC8BB30

Q37190771-66F36915-6956-4F00-897F-07FF74AF211B

Q37190771-789D30C5-8A21-4CEF-8B4F-8B8D72DED6C9

Q37190771-91643029-318A-48E2-A621-93F83E2974DE

Q37190771-A5364DBB-B94C-4903-8B63-3CB1829506E2

Q37190771-D9815A91-82BB-494B-8176-BF3055E66B03

P2860

Q37190771-05EF1672-ABC7-4075-AE2C-AE953247D937

Q37190771-0A2EC88C-7A00-46CE-87A9-CDF3DD691301

Q37190771-0DA96BDC-6CCE-4184-9EDC-14BC9B2906C5

Q37190771-108E1311-7BEF-4EA3-A055-091F2DBF8BC0

Q37190771-1240FD8C-B704-43F8-A171-6A15DC8B6995

Q37190771-1B3D351C-3C0A-4B26-8F6C-6977CCD691FD

Q37190771-1C7550B1-DE46-481A-95C6-9E062FF12459

Q37190771-215A6AD2-F214-4DAB-BCF2-659187A9FD4E

Q37190771-24C81B73-36CB-47F1-B085-80174DDD77BC

Q37190771-2789AA14-A7C3-4051-9B99-4FACE58CF020

P304

Q37190771-E1721063-C839-4BC2-B5C1-AAE098BA105D

P31

Q37190771-581EF287-252E-46CE-A1DA-B6AFC293A077

P356

Q37190771-2A3A933C-482C-4CD0-9C13-249BAB53D1F7

P407

Q37190771-885C45E0-AD8B-40D1-9B08-ECA601A36677

P433

Q37190771-82AF1977-7529-457A-A19B-814AFA68F0C1

P478

Q37190771-B595D367-7B00-4FA1-B4F1-4B2FAA6648D7

P50

Q37190771-C79BD896-212C-4CDF-A430-8F485CD958AA

P577

Q37190771-5C0CD417-9556-4C82-9CF6-1CA0BFF561BE

P698

Q37190771-0C45407F-4BCC-4958-B547-BE68062A4DC3

P921

Q37190771-3A82A7D7-2AA0-482B-AC66-EFE9EADDE517

Q37190771-B7E68C25-E77A-447D-A338-FFDFC7380C36

Q37190771-F0BAA6E3-6AF0-4C2B-86E9-E1F3E108EC4F

P932

Q37190771-672100CD-BA8F-491A-8E70-BF9C7088F54A

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients

@en

P2093

Arnaud Ducruix

http://www.w3.org/2001/XMLSchema#string

Catherine Llanes

http://www.w3.org/2001/XMLSchema#string

Cédric Muller

http://www.w3.org/2001/XMLSchema#string

Farid El Garch

http://www.w3.org/2001/XMLSchema#string

Gilles Phan

http://www.w3.org/2001/XMLSchema#string

Lucie Vettoretti

http://www.w3.org/2001/XMLSchema#string

Patrick Plésiat

http://www.w3.org/2001/XMLSchema#string

P2860

Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen

Biofilms and planktonic cells of Pseudomonas aeruginosa have similar resistance to killing by antimicrobials

Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors

Crystal structure of bacterial multidrug efflux transporter AcrB

Mutations in PA3574 (nalD) lead to increased MexAB-OprM expression and multidrug resistance in laboratory and clinical isolates of Pseudomonas aeruginosa

MexAB-OprM hyperexpression in NalC-type multidrug-resistant Pseudomonas aeruginosa: identification and characterization of the nalC gene encoding a repressor of PA3720-PA3719

Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosa

Involvement of an active efflux system in the natural resistance of Pseudomonas aeruginosa to aminoglycosides

Induction of the MexXY efflux pump in Pseudomonas aeruginosa is dependent on drug-ribosome interaction

Differential effects of mutations in tonB1 on intrinsic multidrug resistance and iron acquisition in Pseudomonas aeruginosa

P304

1987-1997

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.01024-08

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-03-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19258280

http://www.w3.org/2001/XMLSchema#string

P921

cystic fibrosis

Pseudomonas aeruginosa

P932

2681539

http://www.w3.org/2001/XMLSchema#string